Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emilumenib (DS-1594b) in R/R AML and ALL
NCT04752163Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of emilumenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2021; status: terminated.
02
Drugs
emilumenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04752163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752163.